iSpecimen announced the completion of acquiring two Foldlab AI tools—an AI agent for identifying disease-associated proteins and a model to predict disease trends—on November 2, 2026. The addition of AI-enabled discovery and analytics could broaden ISPC's service offering beyond the biospecimen marketplace and potentially drive higher customer engagement, though financial terms and integration milestones were not disclosed.
iSpecimen announced expanded access to fully consented healthy donor whole blood via an existing partner, enabling researchers to source blood collected specifically for research. The expansion could broaden the company's biospecimen supply options and support higher research activity, potentially boosting demand for ISPC's services in the near term.